Skip to main content
Skip to navigation
Print subscriptions
Sign in
Search jobs
Search
International edition
International edition
UK edition
US edition
Australia edition
Europe edition
The Guardian - Back to home
The Guardian
News
Opinion
Sport
Culture
Lifestyle
Show
More
Show More
News
View all News
World news
UK news
Climate crisis
Ukraine
Environment
Science
Global development
Football
Tech
Business
Obituaries
Opinion
View all Opinion
The Guardian view
Columnists
Cartoons
Opinion videos
Letters
Sport
View all Sport
Olympics 2024
Football
Cricket
Rugby union
Tennis
Cycling
F1
Golf
US sports
Culture
View all Culture
Books
Music
TV & radio
Art & design
Film
Games
Classical
Stage
Lifestyle
View all Lifestyle
Fashion
Food
Recipes
Love & sex
Health & fitness
Home & garden
Women
Men
Family
Travel
Money
Search input
google-search
Search
Support us
Print subscriptions
International edition
UK edition
US edition
Australia edition
Europe edition
Search jobs
Holidays
Digital Archive
Guardian Licensing
About Us
The Guardian app
Video
Podcasts
Pictures
Newsletters
Today's paper
Inside the Guardian
The Observer
Guardian Weekly
Crosswords
Wordiply
Corrections
Search jobs
Holidays
Digital Archive
Guardian Licensing
About Us
Novartis
July 2023
‘It’s naive to think this is in the best interests of the NHS.’ How Big Pharma’s millions are influencing healthcare
Observer investigation shows drug company money flows through the NHS, raising questions about conflict of interest
March 2023
Novartis scraps cholesterol drug trial in blow to UK life sciences ambitions
Swiss firm’s withdrawal from Leqvio trial with NHS dents government plans to attract post-Brexit research and investment
January 2020
NHS to trial twice-yearly injection alternative to statins
Mass trial of drug inclisiran comes after health service strikes deal with Novartis
May 2019
The $2m drug reveals medical research as a casino culture
Kenan Malik
$2.1m Novartis gene therapy to become world's most expensive drug
February 2019
Brexit frontline
What are Brexit contingency plans for pharmaceutical industry?
With fears over manufacturing costs and future investment, here’s what firms are doing
January 2019
Drug firm Novartis fears no-deal Brexit could put patients at risk
Swiss company is stockpiling amid concerns about the supply and safety of medicines
November 2018
Big pharma 'failing to develop urgent drugs for poorest countries'
Two-thirds of treatments identified by WHO yet to be developed, says monitor group
September 2018
Fears hundreds of jobs could be axed as Novartis exits Grimsby
Swiss pharmaceutical firm announces it will leave north-east site by 2020, in move not linked to Brexit
May 2018
Top Novartis lawyer steps down over Michael Cohen payments
Nils Pratley on finance
BT v DT: does the German giant want less fibre?
Nils Pratley
Payments to Michael Cohen show how 'shadow lobbying' eludes US law
Robert Mueller investigating payments to Michael Cohen, Swiss drug giant says
March 2018
Horlicks up for sale as GSK looks to fund $13bn Novartis deal
Gender pay gap: what we learned in week three
February 2018
Novartis bribery claims: Greek MPs vote to investigate top politicians
Greece rocked by claims drug giant bribed former leaders
August 2017
US approves first cancer drug to use patient's own cells – with $475,000 price tag
Novartis medication marketed as Kymriah treats most common type of childhood cancer, but some fear it could spur wave of highly expensive drugs
August 2016
Cancer drug companies cut prices to win NHS approval
Give drugs companies credit when it’s due
About 33 results for Novartis
1
2
Explore more on these topics
Pharmaceuticals industry
Health
NHS
GlaxoSmithKline
Pfizer